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Abstract: The early diagnosis of Alzheimer’s disease (AD) has become important to the reversal and
treatment of neurodegeneration, which may be relevant to premature brain aging that is associated
with chronic disease progression. Clinical proteomics allows the detection of various proteins in
fluids such as the urine, plasma, and cerebrospinal fluid for the diagnosis of AD. Interest in lipidomics
has accelerated with plasma testing for various lipid biomarkers that may with clinical proteomics
provide a more reproducible diagnosis for early brain aging that is connected to other chronic
diseases. The combination of proteomics with lipidomics may decrease the biological variability
between studies and provide reproducible results that detect a community’s susceptibility to AD.
The diagnosis of chronic disease associated with AD that now involves genomics may provide
increased sensitivity to avoid inadvertent errors related to plasma versus cerebrospinal fluid testing
by proteomics and lipidomics that identify new disease biomarkers in body fluids, cells, and tissues.
The diagnosis of AD by various plasma biomarkers with clinical proteomics may now require the
involvement of lipidomics and genomics to provide interpretation of proteomic results from various
laboratories around the world.
Keywords: diagnosis; biomarkers; Alzheimer’s disease; lipidomics; genomics; chronic disease;
plasma; cerebrospinal fluid
1. Introduction
In the world approximately 44 million people have been diagnosed with Alzheimer’s disease
(AD) or related dementia. The global cost of AD and dementia has now been estimated to be approx.
$605 billion and is equivalent to 1% of the world’s gross domestic product. In the United States
AD rates by age classifications are: 85+ years, 38%, 75–84 years, 44%, 65–74 years, 15%, <65 years,
4%. The age group under 65 years has been diagnosed with approx. 4% of the AD cases and as
of 2016 the susceptibility to AD may have originated early in life with chronic diseases such as
obesity, diabetes, and neurodegenerative diseases closely associated with hypothalamic disturbances
and neurodegenerative diseases. AD is a neurodegenerative condition that involves disturbances in
multiple higher brain functions including memory and cognition. Amyloid beta is the main constituent
of AD senile plaques [1] and prevention of amyloidosis and dementia may require the diagnosis of
individuals early in life to link chronic disease progression with early neurodegeneration.
In the current global epidemic the incidence of obesity and diabetes has been associated with
non-alcoholic fatty liver disease (NAFLD) and insulin resistance, which in the developing and
developed world may rise to between 30% and 40% of the global population [1,2]. Individuals
homozygous for apo E4 develop AD but non-apo E4 individuals may also develop AD later in
life, linked to chronic disease progression early in life involved in the induction of these AD cases
(75–84 years, 44% AD cases). The association between chronic disease progression and AD indicates
that clinical proteomics (Figure 1) may provide novel biomarkers with a serum protein profile that
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may diagnose early progression to later-life AD. Plasma biomarkers such as amyloid beta have been
an important diagnostic biomarker for AD but non-reproducible and insensitive results for amyloid
beta have been obtained for the diagnosis of AD [3–5].
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Figure 1. In body fluids such as the urine, plasma, and cerebrospinal fluids, the abundance of proteins 
has become of importance in the diagnosis of various chronic diseases including Alzheimer’s disease. 
Testing of these fluids involves biological variation or differences in the sample along with inter- and 
intra-assay variability that may influence proteomics results. Measurement and data analysis of fluid 
proteomics can be improved by comparison with genomic and lipidomic data. Technological 
advances in Alzheimer’s disease (AD) allow interpretation of clinical proteomics, lipidomic, and 
genomic data that may assist in the development of new protein biomarkers with relevance to the 
reversal of chronic disease and the diagnosis of AD.  
The cholesterol–AD connection [6] has attracted considerable interest with relevance to treatment 
with nutritional diets that maintain cell cholesterol homeostasis. The calorie-sensitive anti-aging gene 
Sirtuin 1 (Sirt 1) is closely involved in global disease progression with accelerated NAFLD, adiposity, 
and AD closely linked to Sirt 1 downregulation, hypercholesterolemia, and dementia [1,2]. Sirt 1 is 
one of the nuclear receptors that is known to regulate several cell functions by deacetylating both 
histone and non-histone targets. Sirt 1 is an NAD (+)-dependent class III histone deacetylase protein 
that targets transcription factors to adapt gene expression to metabolic activity, insulin resistance, 
and inflammation in chronic diseases. Dyslipidemia in AD has now become relevant to amyloidosis 
with tissue lipidomic analysis that indicates elevation in sphingolipids (sphingosine 1 phosphate) 
and ceramides in insulin-resistant and AD individuals [1]. Membrane cholesterol and sphingomyelin 
interactions are critical to amyloid beta oligomer formation with increased cellular ceramide levels 
associated with cholesterol displacement in membranes with relevance to amyloidosis and AD [7–9]. 
The interest in clinical lipidomics in AD has accelerated in recent years with relevance to early 
diagnosis by lipidomics of AD when compared with protein biomarker studies and may provide 
reproducible results for late MCI, prodromal disease, and dementia [10–12]. Analysis of a spectrum 
of plasma, tissue, or cerebrospinal fluid lipids (fatty acyls, glycerolipids, glycerophospholipids, 
sphingolipids, sterols, and prenols) assists in the diagnosis of various neurological diseases such as 
AD that are linked to chronic diseases in global populations [13–18]. Furthermore, new blood 
biomarker lipidomic panels have been identified with diagnostic value relevant to the preclinical and 
late stages of AD [19,20]. 
The global deterioration scale created by Reisberg provides the stages of cognitive function for 
those suffering from a primary degenerative dementia such as AD [11]. Stages 1–3 are the pre-
dementia stages and stages 4–7 are the dementia stages. Lipidomic and genomic information have 
become important to the diagnosis of the early stages [1–3] of AD (Figure 1), with abnormalities in 
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Sirtuin 1 (Sirt 1) is closely involved in global disease progression ith accelerated AFLD, adiposity,
and AD closely linked to Sirt 1 do nregulation, hypercholesterole ia, and de entia [1,2]. Sirt 1 is
one of the nuclear receptors that is kno n to regulate several cell functions by deacetylating both
histone and non-histone targets. Sirt 1 is an AD (+)-dependent class III histone deacetylase protein
that targets transcription factors to adapt gene expression to etabolic activity, insulin resistance,
and infla ation in chronic diseases. Dyslipide ia in AD has no beco e relevant to a yloidosis
ith tissue lipido ic analysis that indicates elevation in sphingolipids (sphingosine 1 phosphate)
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interactions are critical to a yloid beta oligo er for ation ith increased cellular cera ide levels
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The interest in clinical lipidomics in AD has accelerated in recent years with relevance to early diagnosis
by lipidomics of AD when compared with protein biomarker studies and may provide reproducible
results for late MCI, prodromal disease, and dementia [10–12]. Analysis of a spectrum of plasma,
tissue, or cerebrospinal fluid lipids (fatty acyls, glycerolipids, glycerophospholipids, sphingolipids,
sterols, and prenols) assists in the diagnosis of various neurological diseases such as AD that are linked
to chronic diseases in global populations [13–18]. Furthermore, new blood biomarker lipidomic panels
have been identified with diagnostic value relevant to the preclinical and late stages of AD [19,20].
The global deterioration scale created by Reisberg provides the stages of cognitive function for
those suffering from a primary degenerative dementia such as AD [11]. Stages 1–3 are the pre-dementia
stages and stages 4–7 are the dementia stages. Lipidomic and genomic information have become
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important to the diagnosis of the early stages [1–3] of AD (Figure 1), with abnormalities in cholesterol
and lipoprotein metabolism [1] closely linked to the late progression of AD with changes in cognition
or behavioral symptoms. Nutritional interventions for AD treatment and prevention in stages 1–3
have become important as the neuron disease that involves nuclear membrane changes induced by
unhealthy diets and toxins is related to the corruption of the plasma and cerebrospinal fluid (CSF)
dynamics, which may be reversible in early stages of the disease [21]. Plasma biomarker measurements
by lipidomics and genomics (Figure 1) may provide more sensitive information compared with CSF
measurements that may lead to erroneous diagnostic interpretations with lack of external quality
assessment [22].
Information obtained from lipidomic and genomic analysis may provide information in relation
to hepatic cholesterol metabolism, which is abnormal early in chronic disease and associated with
neurodegeneration and biomarkers now relevant to diagnosis of early brain changes in individuals
susceptible to AD. The use of lipidomic technology allows the study of the lipid composition of
tissues such as the liver and brain that may determine the peripheral metabolism of cholesterol and
amyloid beta that are important to the early stages of AD [23]. The brain–liver crosstalk is now central
to the metabolism of amyloid beta, with the involvement of adipose tissue of relevance to hepatic
amyloid beta metabolism [2]. Therefore, lipidomic and genomic tests for diagnosis of AD indicate
that nuclear receptors are relevant to connections between insulin resistance, chronic disease, and
AD. Downregulation of liver and brain cell nuclear receptors such as Sirt 1 in stages 1–3 of AD [11] is
linked to chronic diseases (obesity/diabetes) and responsible for glucose, cholesterol, and amyloid
beta metabolism disorders, which are abnormalities in the early stages of AD.
2. Multifactorial Nature of Alzheimer’s Disease Provides Important Links to Early Diagnosis
Proteomics has become important to the understanding of disease diagnosis with the apo E
isoforms (apo E2, E3, and E4) related to the increased risk for AD [21]. Apo E4-related diseases have
been shown to initiate toxic events that lead to synaptic dysfunction and neurodegeneration in AD [24].
The multifactorial nature of AD has raised concerns since apo E4 has also been shown to be involved in
various other diseases such as insulin resistance, cardiovascular disease, hypercholesterolemia, obesity,
and NAFLD [25–28]. Apo-E isoforms regulate Aβ aggregation and clearance in the liver and brain with
effects of brain lipid transport, glucose metabolism, neuroinflammation, and mitochondrial function
on amyloid beta transport [24]. The role of apo E4 in chronic disease progression is well understood
but its role may be secondary compared to the primary role the anti-aging protein Sirt 1 has in nuclear
receptor and transcriptional regulation involved with NAFLD, insulin resistance, mitochondrial
function, neurodegeneration, cardiovascular disease, and AD [2,29–35]. Individuals with apo E3 have
become of major concern for insulin resistance and NAFLD with links to AD [1,2] since NAFLD has
risen to 30% of the global population and a lack of hepatic Sirt 1 activity relevant to the defect in the
peripheral sink beta clearance pathway [23,36,37] associated with accelerated brain amyloidosis [36].
Diagnosis of early AD and neurological disease now involves clinical genomic cell analysis with Sirt 1
(Figure 2), transcriptional dysregulation [2,36,37] involved in appetite, and metabolic disease and
obesity with relevance to hepatic amyloid beta, cholesterol, and glucose metabolism.
Clinical genomic testing (apo E) plays a major role in the diagnosis of AD and avoids inadvertent
errors related to plasma versus CSF testing by proteomics and lipidomics that identify early and novel
disease biomarkers in body fluids, cells, and tissues. Nutritional regulation of Sirt 1 in peripheral cells
determines the peripheral clearance pathways for amyloid beta involving apolipoprotein E (apo E)
and albumin [38,39]. Brain amyloid beta clearance [21,36] is secondary to nutritional regulation with
the role of the liver Sirt 1 central and important to spontaneous brain abeta aggregation (oligomers
and fibrils). Sirt 1 gene expression (Figure 2), especially its effects on transcriptional regulation and
DNA methylation [2,35,40] in cells, has become of importance and may supersede apo E genotyping
in cells for differential diagnosis of early AD.
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Figure 2. Discovery of biomarkers that are consistent with the stages of development of AD and 
involve progression that includes mild cognitive impairment, prodromal disease, and the 
development of dementia. Proteomics that involve 10 plasma protein predictors (AD/dementia) and 
acute phase proteins (MCI/prodromal disease) allow detection of the severity of the stages of AD. 
Interest in genomics has accelerated with the identification of the calorie-sensitive gene Sirt 1, which 
may allow early AD diagnosis when compared to relevant proteomic/lipidomic biomarkers 
(ceramides, sphingolipids) that are involved in the later stages of AD. Interventions with nutritional 
therapy may activate cell Sirt 1/transcriptional regulation and maintain glucose, cholesterol, and 
amyloid beta levels connected to the delay in the progression and severity of AD (stages 4–7). 
Furthermore, multiple technologies may separate and diagnose individuals with other neurological 
disease from AD that may involve plasma, CSF, and tissue analysis.  
Sirt 1 increases adiponectin transcription in adipocytes [2] by activation of forkhead transcription 
factor O1 (Foxo) interaction with CCAAT/enhancer-binding protein alpha (C/EBPalpha) to form a 
transcription complex at the mouse adiponectin promoter that upregulates adiponectin gene 
transcription [41]. Sirt 1 interactions with C/EBPalpha may involve Klotho C/EBPalpha and peroxisome 
proliferator-activated receptor (PPAR) interactions [2,42–44] with their important role in adipocyte 
differentiation. Dietary downregulation of Sirt 1 contributes to reduced adiponectin expression in 
obesity and diabetes [41] with effects on adipose tissue transformation and liver development [45]. 
Fibroblast growth factor 21 (FGF21) is an important activator of Sirt 1-mediated release of adiponectin 
[46]. FGF21 binds to FGF receptor and beta koltho receptor complex [47–51] and activates adipose 
tissue Sirt 1 by increases in NAD+ and activation of peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC1-alpha) and AMP-activated protein kinase (AMPK) [46,52]. Nutrition and 
PPAR alpha-Sirt 1 expression related to hepatic FGF21 production has become important to NAFLD and 
the metabolic syndrome [53–57]. FGF21 is regulated by fasting and feeding and with vasoactive intestinal 
peptide (VIP) associated with the circadian brain–liver amyloid beta clearance pathway [51,58–61] 
(Figure 3). 
Figure 2. Discovery of biomarkers that are consistent with the stages of development of AD and
involve progression that includes mild cognitive impairment, prodromal disease, and the development
of dementia. Proteomics that involve 10 plasma protein predictors (AD/dementia) and acute phase
proteins (MCI/prodromal disease) allow detection of the severity of the stages of AD. Interest in
genomics has accelerated with the identification of the calorie-sensitive gene Sirt 1, which may
allow early AD diagnosis when compared to relevant proteomic/lipidomic biomarkers (ceramides,
sphingolipids) that are involved in the later stages of AD. Interventions with nutritional therapy may
activate cell Sirt 1/transcriptional regulation and maintain glucose, cholesterol, and amyloid beta levels
connected to the delay in the progression and severity of AD (stages 4–7). Furthermore, multiple
technologies may separate and diagnose individuals with other neurological disease from AD that may
involve plasma, CSF, and tissue analysis.
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Figure 3. Fibroblast growth factor 21 (FGF21) regulates Sirt 1-mediated release of adiponectin from 
adipose tissue with relevance to NAFLD and the metabolic syndrome. Micro RNA, Sirt 1, and 
transcription factor interactions are possibly involved in vasoactive intestinal peptide (VIP)-mediated 
release of ADNP from neurons with critical links of Sirt 1 and ADNP in neuron survival. FGF21, Sirt 1, 
and VIP are associated with the circadian brain–liver amyloid beta clearance pathway with decreased 
VIP levels in plasma associated with excess sodium intake and sodium intake linked to adiponectin 
levels. Sirt 1’s downregulation, associated with insulin resistance, is linked to high plasma sodium levels 
and low plasma VIP levels. This is related to its vascular effects in the central nervous system, which 
determine hepatic amyloid beta metabolism and the regulation of apo E-mediated amyloid beta 
clearance pathways in the brain.  
Low adiponectin levels and hypercholesterolemia with low high density lipoproteins (HDL) 
apolipoprotein AI levels and high low density lipoprotein (LDL) apolipoprotein B levels have been 
associated with insulin resistance and AD (Figure 3) [1]. Research into adiponectin and its regulation 
of ceramide metabolism (Figure 2) has shown that the effects on sphingolipid (sphingosine-1-
phosphate) metabolism are connected to pancreatic insulin production [62–65]. Adiponectin 
deficiency has been shown to reduce hepatic ATP-binding cassette transporter ABCA1 (ABCA1) and 
apo AI synthesis with relevance to the reverse cholesterol transport [66]. Hepatic FGF21 has been 
shown to regulate lipolysis (fatty acid release) with FGF21 critical in the reduction of adipose tissue 
ceramides. In insulin resistance and AD, FGF21 and adiponectin levels are implicated in increased 
cellular ceramide levels associated with cholesterol displacement in membranes with relevance to 
amyloidosis and AD [7–9]. Sirt 1/adiponectin/FGF21 dysregulation determine hepatic cholesterol 
metabolism with effects on plasma apo B levels mediated via Sirt 1 and transcription factor C/EBPalpha, 
which regulates the transcription of the apo B gene [67]. Sirt-regulated transcription factors such as 
hepatocyte nuclear factor 4 (HNF4) and PGC1 alpha have been shown to modulate hepatic 
apolipoprotein synthesis with relevance to hepatic lipid metabolism [68–71]. 
Sirt 1 gene expression and its regulation early in life is central to hepatic glucose, cholesterol, 
and amyloid beta metabolism and their downregulation in stages 1–3 of AD (Figure 2) avoid errors 
with relevance to proteomic (adiponectin, FGF21) and lipidomic (ceramides, sphingolipids) analysis 
that may show increased or altered levels in plasma and CSF in later stages 4–7 of AD. Sirt 1’s role in 
circadian rhythms [72,73] and neuron survival is shown by connections to the circadian neuron 
regulation by the neuropeptide vasoactive intestinal peptide (VIP) [74–77] mediated via the activity-
dependent neuroprotective protein (ADNP) release from astrocytes and the protection of neurons 
(Figure 3) [78–83]. Decreased VIP levels in plasma are associated with excess sodium intake [84,85] 
and sodium intake linked to adiponectin levels [86]. Sirt 1’s links to insulin resistance (Figure 3) are 
associated with high plasma sodium levels [87–89] and low VIP levels, which contribute to coronary 
events [90] and vascular effects in the central nervous system that determine peripheral amyloid beta 
metabolism and transport of amyloid beta across the blood–brain barrier [91,92] and are important to 
Figure 3. Fibroblast growth factor 21 (FGF21) regulates Sirt 1-mediated release of adiponectin from
adipose tissue with relevance to NAFLD and the metabolic syndrome. Micro RNA, Sirt 1, and
transcription factor interactions are possibly involved in vasoactive intestinal peptide (VIP)-mediated
release of ADNP from neurons with critical links of Sirt 1 and ADNP in neuron survival. FGF21, Sirt 1,
and VIP are associated with the circadian brain–liver amyloid beta clearance pathway with decreased
VIP levels in plasma associated with excess sodium intake and sodium intake linked to adiponectin
levels. Sirt 1’s downregulation, associated with insulin resistance, is linked to high plasma sodium
levels and low plasma VIP levels. This is related to its vascular effects in the central nervous system,
which determine hepatic amyloid beta metabolism and the regulation of apo E-mediated amyloid beta
clearance pathways in the brain.
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important to the role of VIP in the regulation of apo E-mediated amyloid beta clearance pathways in
the brain and the liver [21,23,93].
Micro RNAs and neuron survival have become important, with micro RNA 34a (miR 34a),
which inhibits Sirt 1, relevant to metabolic diseases and neurogenesis (Figure 3), possibly through
interactions with hepatocyte nuclear factor (HNF4/HNF1) alpha (MODY gene), which may be relevant
to the diagnosis of NAFLD and neurodegenerative diseases [2,94–96]. Interference of HNF4/PGC1
alpha by the transcription factor pregnane X receptor (PXR) is possibly connected to Sirt 1 regulation
of PXR-mediated modulation of HNF4/PGC1 alpha, which is important for drug and cholesterol
metabolism [18,97]. Sirt 1 deacetylation of the transcription factor p53 [2] mediates the effects of
PXR with respect to HNF4/PGC1 alpha regulation [98,99] of hepatic cholesterol metabolism and
amyloid beta metabolism, and also involves p53’s effects on VIP with ADNP release from neurons
(Figure 3) [100]. Nutritional regulation and insulin resistance, which rely on miR 34a/Sirt 1 involvement
in HNF-1/HNF4 interactions [101,102], are central to the links between the genetic regulation of
diabetes and neurogenesis [36,96,103].
Interest in the field of proteomics has accelerated to determine the plasma biomarkers that provide
increased sensitivity so as to avoid inadvertent errors related to plasma versus CSF markers for the
reproducible diagnosis for AD. Biomarker studies that are consistent with the stages of development of
specific brain changes in AD involve progression from no clinical manifestation to a prodromal stage
with mild cognitive impairment and the development of final prodromal disease with dementia [10–12].
The plasma biomarkers involved in oxidative stress and inflammation that may be important to early
diagnosis for AD (no clinical manifestation) are the hepatic acute phase reactants/cytokines (APP)
involved in amyloid beta homeostasis with corruption of apo E-mediated cholesterol transport [21,23].
Acute phase proteins that directly interact with amyloid beta oligomers include serum amyloid protein
P, serum amyloid protein A, alpha 2 macroglobulin, gelsolin, complement components, transthyretin,
and clusterin [21]; these biomarkers assist with the early diagnosis of AD (Figure 2).
In a multiplexing approach a plasma protein panel has been identified to assess disease severity
for predicting disease progression from prodromal disease to dementia. Ten proteins have been
identified to diagnose AD [10]: include transthyretin, clusterin, cystatin C, alpha 1 acid glycoprotein,
intercellular adhesion molecule 1, complement C4 , pigment epithelium-derived factor, alpha 1
antitrypsin, RANTES, and apolipoprotein C3. These plasma protein biomarkers important to AD
diagnosis overlap with CSF protein measurements in other neurological diseases [104–112]. Other
novel proteomic candidate markers have been identified recently and promise to diagnose the very
early and late stages of AD [113]. Furthermore, the activity-dependent neuroprotector homeobox
protein has been shown to be downregulated in AD and may also be an important diagnostic marker
for AD [81]. Proteomics that involve clinical biomarker discovery allow detection of severity for AD
but the specific role of genomics such as cellular Sirt 1 may be to allow early diagnosis with Sirt
1 activation associated with relevant proteomic biomarkers (Figure 2) involved in the delay of the
severity of disease progression from MCI to prodromal disease and dementia [114–119].
Nutritional research, involved in the activation of hepatic Sirt 1, which increases
the low adiponectin levels associated with metabolic syndrome, platelet aggregation, and
angiogenesis [119–123], is now required. Adiponectin has been shown to form protein complexes with
alpha2-macroglobulin and thrombospondin-1 (TSP-1). Alterations in adiponectin levels determine
alpha2–macroglobulin–amyloid beta interactions and TSP-1–amyloid beta interactions [124–127],
which involve binding to cell receptors such as low-density lipoprotein receptor-related protein and
heparin sulphate proteoglycans [128,129], showing a relationship between TSP-1 and amyloid beta
in post-prandial lipid metabolism [37]. Adiponectin is important in astrocyte-neuron amyloid beta
metabolism [1], with the effects of adiponectin on brain–liver amyloid clearance determined by proteins
such as alpha 2 macroglobulin and TSP-1. TSP-1 is a matricellular protein involved in inflammation
and in interactions with various proteins, platelet aggregation, and nitric oxide dyshomeostasis
associated with cardiovascular disease, stroke, and diabetes [129–139]. TSP-1 is important to neuron
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synaptogenesis, with astrocyte TSP-1 release [125] determined by brain adiponectin content with
effects on astrocyte-neuron amyloid beta clearance [1]. Genomics and proteomics may assist in the
early diagnosis of AD through the primary role of the gene Sirt 1, adiponectin, and TSP-1 in amyloid
beta homeostasis, while the corruption of liver and brain regulation has an effect on amyloid beta
metabolism [21,23].
TSP-1 regulates transforming growth factor beta (TGF-β) levels with effects on TGF-β signaling,
which determines TGF-β partitioning between lipid raft/caveolae- and clathrin-mediated endocytosis
pathways [140–144]. Interactions between TSP-1 and TGF-β determine cell liver cholesterol
(post-prandial lipid metabolism) [37] and peripheral amyloid beta homeostasis, which are relevant
to chronic liver disease, NAFLD, atherogenesis, brain apoptosis, and AD [145–151]. The anti-aging
protein GDF11, which belongs to the TGF-β family, has been shown to restore muscle and brain
function [152,153], while the role of TSP-1 in the regulation of GDF11 needs to be determined.
3. Nutriproteomic Diets Regulates Plasma Biomarkers and Reverses Neurodegeneration
and Amyloidosis
Clinical biomarker discoveries have become important with nutriproteomics [154–156] as a
technology that could determine biomarkers that may assist with the maintenance of normal cognitive
development in individuals at risk of AD. The ingestion of nutrients allows proteomic tools to
characterize molecular and cellular changes in protein expression and function in the plasma and
CSF [157–160] with respect to nutritional diets that activate the anti-aging gene Sirt 1 and allow
proteins such as amyloid beta/alpha synuclein to maintain monomer interactions and prevent
self-association that induces inflammation [38,39]. Low-calorie diets (glucose, fatty acids) regulate
Sirt 1/adiponectin expression and nuclear interactions that involve nuclear receptors, transcription
factors, and microRNAs that determine liver apo AI/apo B kinetics and ceramide metabolism with
respect to amyloid beta metabolism in non-diabetic and diabetic individuals [161]. Integration of
proteomics, lipidomics, and genomics technologies allows for the interpretation of various nutritional
and dietary interventions that assist in the reversal of neurodegeneration in late MCI, prodromal
disease, and dementia.
Nutritional research (low fat diets) that targets the intestine lowers the absorption of bacterial
lipopolysaccharides (LPS) that have effects on acute inflammation, which involves lymphocytes,
monocytes, and macrophages that stimulate tumor necrosis factor alpha (TNF-α) secretion from
cells [162]. LPS induces NAFLD and insulin resistance, with insulin resistance linked to alterations
in plasma/CSF sodium levels [163] (Figure 4). LPS alter apo E and amyloid beta interactions with
accelerated amyloidosis [37,39,162,164] associated with biomarkers such as hepatic cytokines and
APP-associated inhibition of reverse cholesterol transport [1,23]. Nutriproteomic diets, such as high
fiber diets [6,135], have become important now that inflammatory regulation associated with LPS
repression of Sirt 1 [21,37] has been linked to atherogenic diets. Nutriproteomic diets such as very low
carbohydrate diets maintain the circadian rhythm, brain–liver amyloid beta pathways, and sodium
balance [165], reverse cholesterol transport involving adiponectin [86,166,167], and prevent cognitive
decline, cardiovascular disease, and diabetes. These diets involve the measurements of plasma/CSF
levels of adiponectin, FGF21, VIP, Klotho, IGF-1, TSP-1, TGF-beta, and gelsolin and may be relevant to
healthy dietary interventions (Figure 4).
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expression and increases TSP-1 release from cells with effects on adiponectin and peripheral amyloid
beta/cholesterol clearance pathways. Nutritional therapy reduces LPS-induced inflammation and
maintains hepatic TGF-β/cholesterol levels (apo AI, apo B); these nutriproteomic diets avoid the
transfer of LPS/mycotoxin from the blood plasma to the CSF to prevent LPS/mycotoxin-induced
brain apo E neutralization associated with the pr ventio of amyloidosis and neurodegenerati n. Low
calorie diets maintain plasma anti-aging protein GDF11, FGF21, VIP, gelsolin, insulin like growth factor
1 (IGF-1), and klotho levels, which are relevant to chronic diseases and AD.
Interventions with nutriproteomic diets in individuals with MCI to prodr mal disease and
dementia may allow activation of Si t 1/adipon cti expression with the identification of changes in
plasma/CSF biomarkers (Figure 3) relevant to treatment of individuals with severe forms of prodromal
disease and dementia. Furthermore, high fat diets increase adipose tissue TSP-1 levels [168,169] and
thus the risk for cardiovascular disease, neuron dysfunction, and defective NO pathways. Sirt 1
regulation of endothelial NOS has been reported with respect to neuroprotection and vascular-related
diseases [170]. Diets that reduce TSP-1 improve adipose tissue apelin/Sirt 1 eff cts on nitric
oxide disturbances and vasoconstriction [170]. Angiotensin II is critical to the regulation of TSP-1
levels in cells [171,172], with apelin/angiotensin II/TSP-1 interactions affecting toxic amyloid beta
generation [170]. The effects of TSP-1 on inflammation involve TNF-α [173–175], which is relevant to
the treatment of cognitive impairment and neuron dysfunction [176,177]. Adiponectin expression and
TNF-α expression are connected with low adiponecti levels, which are associated with high TNF-α
levels [178]. Adiponectin pretreatment has been shown to reduce hepatic TNF-α levels with inhibition
of LPS-induced effects in the liver [179] and maintenance of apo E activity [162,164] involved in the
reduction of TNF-α secretion [180–182]. Low fat diets are possibly important in the maintenance of
hepatic Sirt1/adiponectin expression, with inhibition of LPS/TNF-α effects and maintenance of FGF21
effects in the adipose tissue [183–186] and VIP effects in the liver (apo E mediated) allowing for the
clearance of peripheral amyloid beta [51].
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Diets that contain zinc may maintain Sirt 1 expression [21] and prevent abnormal LPS/zinc
interactions. Zinc is sensitive to HNF4 [187] and reduced hepatic TNF-α toxicity [188,189] may aid the
prevention of insulin resistance and AD [1]. Nutriproteomic diets as a treatment for reduction of LPS
effects may lower TSP-1 expression by peripheral cells [190–192] and improve peripheral LPS–protein
interactions [193–196] to accelerate peripheral amyloid beta metabolism with respect to treatment of
individuals with prodromal disease and dementia. Nutritional diets that activate Sirt 1 and maintain
therapeutic VIP and FGF21 levels [51] accelerate hepatic LPS/mycotoxin metabolism without transfer
to the CSF and brain compartment [21], which is consistent with the use of nutritional therapy to
maintain CSF composition, recycling, and amyloid beta dynamics [197,198] for the prevention of early
neurodegeneration (stages 1–3) and amyloidosis.
4. Conclusions
The susceptibility to AD earlier in life may now involve chronic diseases such as obesity,
diabetes, and neurodegenerative diseases. Nutritional interventions and early diagnosis may reduce
spontaneous amyloid beta oligomerization associated with the excessive global cost ($605 billion)
of late onset AD (>65 years). In the global crisis the inflammatory effects of LPS on apo E/Sirt 1
neutralization reaction induce increased TSP-1 levels that may be relevant to multifactorial diseases
including cardiovascular diseases, NAFLD, and neurodegenerative diseases. Nutritional interventions
are required to reduce the absorption of LPS early in life to prevent induction of inflammation
linked to circadian abnormalities, accelerated amyloidosis metabolic disease, and neurodegeneration.
Technologies of lipidomics, genomics, and proteomics are required to assess early plasma lipid
and protein biomarkers that indicate repression of nuclear Sirt 1, which involves oxidative stress,
inflammation associated with programmed cell death in chronic diseases, and early stages of AD
(Reisberg). The genomic, lipidomic, and proteomic interpretation may provide evidence that apo
E/Sirt 1 repression and liver disease in global populations is the major defect in early and late stages
of MCI with links to prodromal disease and dementia.
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